WO2009115874A3 - Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation - Google Patents
Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation Download PDFInfo
- Publication number
- WO2009115874A3 WO2009115874A3 PCT/IB2009/000190 IB2009000190W WO2009115874A3 WO 2009115874 A3 WO2009115874 A3 WO 2009115874A3 IB 2009000190 W IB2009000190 W IB 2009000190W WO 2009115874 A3 WO2009115874 A3 WO 2009115874A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heterocyclic compounds
- phosphodiesterase
- novel heterocyclic
- disorders
- processes
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 208000003401 eosinophilic granuloma Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel heterocyclic compounds of general formula (I) that are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors. These novel PDEs are useful in the treatment of inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) as well as disorders or conditions generally characterized by or associated with an excessive secretion of TNF-α and Phosphodiesterase 4 (PDE IV).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN656/CHE/2008 | 2008-03-17 | ||
| IN656CH2008 | 2008-03-17 | ||
| IN2228CH2008 | 2008-09-12 | ||
| IN2228/CHE/2008 | 2008-09-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009115874A2 WO2009115874A2 (en) | 2009-09-24 |
| WO2009115874A3 true WO2009115874A3 (en) | 2009-11-12 |
Family
ID=40626904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2009/000190 WO2009115874A2 (en) | 2008-03-17 | 2009-01-29 | Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009115874A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| NZ611323A (en) | 2006-06-23 | 2014-10-31 | Abbvie Bahamas Ltd | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| JP6064062B2 (en) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Indazole compounds that activate AMPK |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CN112574218A (en) * | 2020-12-30 | 2021-03-30 | 广州安岩仁医药科技有限公司 | Synthesis method of indole or azabenzopyrrole compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006011024A2 (en) * | 2004-07-19 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
-
2009
- 2009-01-29 WO PCT/IB2009/000190 patent/WO2009115874A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006011024A2 (en) * | 2004-07-19 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009115874A2 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009115874A3 (en) | Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation | |
| EA200970852A1 (en) | PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PHOSPHODESTERASE INHIBITORS | |
| WO2008035315A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| MY143483A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| EA201291273A1 (en) | KINAZ INHIBITORS REGULATING APOSCOPIC SIGNAL | |
| WO2008020302A3 (en) | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors | |
| NZ601267A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| SG155909A1 (en) | Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors | |
| WO2007146838A3 (en) | Substituted phenyl acetic acids as dp-2 antagonists | |
| MX365781B (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases. | |
| WO2008001182A8 (en) | Tricyclic heteroaryl compounds as pde10 inhibitors | |
| MX2009002171A (en) | Triazole derivatives as kinase inhibitors. | |
| ECSP088813A (en) | AMINO-PYRIMIDINE COMPOUNDS 2,6-SUBSTITUTED-4-MONOSUSTITUTED AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEIVER | |
| WO2007077490A3 (en) | Bicyclic heteroaryl compounds as pde10 inhibitors | |
| MX2012013082A (en) | 2 -aminopyridine derivatives useful as inhibitors of atr kinase. | |
| WO2011051342A8 (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
| WO2010142766A3 (en) | Pyrimidine derivatives as zap-70 inhibitors | |
| WO2011143425A3 (en) | Compounds useful as inhibitors of atr kinase | |
| WO2011143423A3 (en) | Compounds useful as inhibitors of atr kinase | |
| WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
| NO20091489L (en) | Thiazole pyrazolopyridines as CRF1 receptor antagonists | |
| TW200639151A (en) | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| WO2007143745A3 (en) | Substituted phenyl acetic acids as dp-2 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09722990 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09722990 Country of ref document: EP Kind code of ref document: A2 |